Reta + Cagri Blend
Next gen triple agonist + amylin fat loss blend (Retatrutide / Cagrilintide)
Next gen triple agonist meets amylin — the emerging heavyweight fat loss stack.
Research chemical vendors can't legally label products with the real name, so Reta + Cagri Blend often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:
- CagriSema
- Reta+Cagri
- 3R + Cagri
Codes shown are for identification only. Always verify third-party COAs before purchase.
Combines Retatrutide (GLP-1 + GIP + glucagon triple agonist) with Cagrilintide (amylin analog). Retatrutide already produces the largest weight loss of any incretin in trials; adding amylin extends satiety and may protect lean mass during aggressive cuts.
Highly potent — start at low doses and titrate. GI side effects and fatigue are more common than with sema/cagri.
- Maximum effect fat loss protocols
- Users who have plateaued on tirzepatide or reta alone
- Improved satiety and glucose response vs. reta monotherapy
- Weekly dosing convenience
Educational only · Not a vendor claim
Retatrutide triple agonizes GLP-1, GIP, and glucagon receptors — the glucagon arm adds direct fat oxidation on top of appetite control. Cagrilintide layers amylin driven satiety and lean mass preservation on top.
- Largest observed fat loss potential of any current blend
- Amylin arm helps preserve lean mass
- Improved insulin sensitivity
- Reduced hepatic fat
- Aggressive appetite suppression
- Weight loss curves steeper than tirzepatide or sema
- Improved metabolic markers within weeks
- Cutting edge stack
- Weekly dosing
- Addresses multiple pathways simultaneously
- Very potent — side effects more common
- Long term human safety data still emerging
- Requires careful titration
- Nausea, GI upset, fatigue
- Increased heart rate in some users
- Rare gallbladder issues at higher doses
Educational summary · Not medical advice · Discuss with a qualified clinician
Typical timeline
General pattern for the Fat Loss category. Individual response varies.
- Week 1Titrate up slowly. Expect appetite drop, mild nausea, and possible constipation with GLP-1s. Hydrate and lean on fiber.
- Weeks 2–4Steady weight trend down (0.5–1.5 lb/week is healthy). Prioritize protein (~1 g/lb lean mass) to protect muscle.
- Weeks 4–8Body composition visibly shifts. Add resistance training if you haven't — muscle preservation is the whole game.
- Weeks 8+Re-evaluate dose. Consider a maintenance drop or a scheduled break to reset receptor sensitivity.
The reconstitution math
- 1Reconstitute the 15 mg vial with 2 mL of bacteriostatic water. Tilt — don't shake.
- 2Concentration becomes 7,500 mcg/mL (7.5 mg/mL).
- 3For a 750 mcg dose, draw 0.100 mL — that's 10 units on a 1 mL insulin syringe.
- 4One vial gives you approximately 20 doses.
Reminder: 100 units on an insulin syringe = 1 mL. Always start at half the listed dose for the first week and rotate injection sites between arms, legs, abdomen, and glutes.
Sign in to keep a private log of your doses and notes for Reta + Cagri Blend.
Use code ANYPEPTIDES15 for 15% off your order.
Discount may end or change without notice.